What kind of inhibitor is 2 deoxyglucose?
Recent molecular studies indicate that aerobic glycolysis plays an important role in tumorigenesis and is a valid target for cancer therapy. Although 2-deoxyglucose (2-DG) is well characterized as a glycolytic inhibitor, we recently discovered that it activates a prosurvival oncoprotein, AKT, through PI3K.
What does 2 deoxyglucose do to the body?
Acting as a d-glucose mimic, 2-DG inhibits glycolysis due to formation and intracellular accumulation of 2-deoxy-d-glucose-6-phosphate (2-DG6P), inhibiting the function of hexokinase and glucose-6-phosphate isomerase, and inducing cell death.
What enzyme does 2-DG inhibit?
2-DG, the glucose analog, acts as a competitive inhibitor of the glycolytic enzyme hexokinase26.
Is 2 deoxyglucose a competitive inhibitor?
Although metrizamide, 2-deoxyglucose, and glucosamine are known to be competitive inhibitors of approximately equal potency for glucose of yeast hexokinase (Ki approximately 0.7 mM for all three), metrizamide is a much weaker competitive inhibitor (Ki about 20 mM) of rat brain hexokinase than either 2-deoxyglucose or …
Is 2-deoxyglucose a competitive inhibitor?
What does 2 deoxy D glucose inhibit?
2-Deoxy- d-glucose is a glucose molecule which has the 2-hydroxyl group replaced by hydrogen, so that it cannot undergo further glycolysis. As such; it acts to competitively inhibit the production of glucose-6-phosphate from glucose at the phosphoglucoisomerase level (step 2 of glycolysis).
What are inhibitors of glycolysis?
Most of the reported glycolysis inhibitors are summarized (Table 1 and Figure 1). The enzymes targeted include hexokinase (HK), phosphofructokinase (PFK), pyruvate kinase (PK), lactate dehydrogenase (LDH), and pyruvate dehydrogenase kinase (PDK).
What are the inhibitors of TCA cycle?
NADH inhibits all the regulatory enzymes in the TCA cycle. Thus, in situations of ETC malfunctioning, NADH accumulates and the TCA cycle shuts down as a consequence. As NADH generates ATP through the ETC and OXPHOS, ATP is also an allosteric inhibitor of pyruvate dehydrogenase (PDH) and IDH.
What are glycolysis inhibitors?
These glycolytic inhibitors are especially effective against cancer cells with defective mitochondria or are under hypoxic conditions, since hypoxia is present in most tumor micro environment. The development of novel glycolytic inhibitors as anticancer agents is bound to have broad therapeutic applications.